References
- Mansford KR, Slocombe B. The evolution of antibiotic production and public health problems. Chemioterapia 1987; 6: 234–40.
- Tenover FC. Development and spread of bacterial resis-tance to antimicrobial agents: an overview. Clin Infect Dis 2001; 33 Suppl 3:S108–S115.
- Bantar C, Sartori B, Vesco E, et al. A hospitalwide inter-vention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37: 180–6.
- Lan CK, Hsueh PR, Wong WW, et al. Association of antibiotic utilization measures and reduced incidence of infec-tions with extended-spectrum beta-lactamase-producing organ-isms. J Microbiol Immunol Infect 2003; 36: 182–6.
- Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumo-niae. Infect Control Hosp Epidemiol. 2000; 21: 455–8.
- Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Contr Hosp Epidemiol 2003; 24: 699–706.
- Hughes MG, Evans HL, Chong TW, et al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-inten-sive care unit ward. Crit Care Med 2004; 32: 53–60.
- Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of van-comycin-resistant enterococci in response to antimicrobial for-mulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003; 36: 440–6.
- Martin C, Ofotokun I, Rapp R, et al. Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm. 2005; 62: 732–8.
- May AK, Melton SM, McGwin G, Cross JM, Moser SA, Rue LW. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000; 14: 259–64.
- Thurmann PA, Harder S, Steioff A. Structure and activ-ities of hospital drug committees in Germany. Eur J Clin Pharmacol. 1997; 52: 429–35.
- Lemmen SW, Hafner H, Kotterik S, Lutticken R, Topper R. Influence of an infectious disease service on antibi-otic prescription behavior and selection of multiresistant pathogens. Infection 2000; 28: 384–7.
- Barenfanger J, Short MA, Groesch AA. Improved antimicrobial interventions have benefits. J Clin Microbiol 2001; 39: 2823–8.
- Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004; 53: 290–6.
- Regal RE, DePestel DD, VandenBussche HL. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy 2003; 23: 618–24.
- Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resis-tance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2920–5.
- Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28: 1062–6.
- Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233–7.
- Platsouka E, Zissis NP, Portolos J, Paniara O. Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review. J Chemother. 2003; 15: 27–30.
- Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J AntimicrobChemother 2000; 45: 183–9.
- Wang H, Chen M. Surveillance for antimicrobial resis-tance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002. Diagn Microbiol Infect Dis 2005; 51: 201–8.
- Livermore DM, Mushtaq S, James D, et al. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int J Antimicrob Agents 2003; 22: 14–27.